-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cerebrospinal fluid amyloid Aβ1–42, total Tau (tTau) and phosphorylated Tau on threonine 181 (pTau181), are important biomarkers for Alzheimer's disease (AD) and are currently included in the national elderly Alzheimer’s It is used in the medical guidelines of the Institute of Murder Society for the diagnosis of AD in a research environment
.
Many centers in the world have adopted a ratio of 1-40 (ratio of 1-40) to diagnose AD early
diagnosis
Plasma tTau lacks disease specificity in AD, but it recognizes neuronal damage well in acute brain diseases
.
Simoa technology also allows the quantification of neurofilament (NfL) in plasma or serum, and shows a good correlation with the measurement results in cerebrospinal fluid
In the current work, the effects of plasma levels of A, T and N markers (Aβ, pTau181 and NfL) on patients with different neurodegenerative dementias are quantified
.
The correlation between plasma biomarkers and biomarkers in cerebrospinal fluid was evaluated, and their respective diagnostic accuracy was evaluated to detect the plasma level of each type of marker
The correlation between plasma biomarkers and biomarkers in cerebrospinal fluid was evaluated, and their respective diagnostic accuracy was evaluated to detect the plasma level of each type of marker
Correlation between AT(N) plasma biomarkers and AT(N) cerebrospinal fluid biomarkers
A total of 150 participants from the SPIN cohort were included, including MCI (n=46), AD (n=8), DLB (n=25), FTLD-related syndromes (n=25) and 46 CN participants
.
The FTLD-related clinical syndrome group includes behavioral variant frontotemporal dementia (n=10), primary progressive aphasia (n=8), cortical basilar artery syndrome (n=4), and progressive supranuclear palsy ( n=2) and frontotemporal dementia related to motor neuron disease (n=1)
The diagnostic accuracy of AT(N) plasma biomarkers on the cerebrospinal fluid (CSF) section
The area under the curve (AUC) of plasma Aβ, pTau181, and NfL were 0.
75, 0.
78, and 0.
88, respectively, which were used to distinguish between positive and negative participants in the A, T, and N categories
.
In distinguishing A+T+ and AT- subjects, the combination of these three indicators is not superior to pTau181 alone (AUC=0.
Plasma biomarkers help to detect the type of AT (N), and its application can be distinguished from the pathophysiological evidence of AD, and blood AT (N) markers are helpful for early diagnosis and follow-up of AD
.
.
AlcoleaD ,DelabyC ,MuñozL AlcoleaD Alcolea DelabyC Delaby MuñozL Muñoz , et al Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias Journal of Neurology, Neurosurgery & PsychiatryPublished Online First:08 June 2021.
Published Online First: doi:10.
1136/jnnp-2021-326603 doi: leave a message here